Q Fever and Auto-immunity

Study Overview
=================
Brief Summary
-----------------
The IHU Mediterranean infection is national reference centre for Q fever. Coxiella burnetii is the bacteria responsible of this infection. The bacterium Coxiella burnetii infection is associated with secretion by the body both many antibodies against the bacteria but also against certain cells of the body (autoantibodies). These autoantibodies may have no effect or be associated with specific symptoms. Anti-Phospholipid antibodies are especially prevalent in the Q fever. Apart from this infection, they are associated with thrombocytopenia, obstetric complications, thrombosis and heart valve damage. These conditions have also been described as complications during Q fever. In a retrospective preliminary work on Q fever, we have shown that the presence of high levels of IgG anti-cardiolipin was associated with the presence of valvular and the evolution to endocarditis. Such associations have a therapeutic involvement and must therefore be confirmed. Indeed, if these associations were confirmed, a trans-esophageal ultrasound could be systematically proposed to patients with valvular disease of trans-thoracique ultrasound but IgG anticardiolipin high levels. Other special attention could be given to patients with high autoantibodies.

Official Title
-----------------
Q Fever and Auto-immunity

Conditions
-----------------
Q Fever, Auto-Immunity

Intervention / Treatment
-----------------
* Biological: Blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a current or former Q fever diagnosis Patient > or = 18 years old. Patient who does not declined to have his medical records reviewed for research. Patient with health insurance. Exclusion Criteria: Minor patient (<18 years ) Adult patient under guardianship . Patient deprived of liberty or judgment. Patient refusing to sign the informed consent form .

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Q fever without valvular disease<br>Q fever without valvular disease | Biological: Blood sampling<br> <br> |
| Other: Q fever with valvular disease<br>Q fever with valvular disease | Biological: Blood sampling<br> <br> |
| Other: Q fever infective endocarditis<br>Q fever infective endocarditis | Biological: Blood sampling<br> <br> |
| Other: Other Coxiella burnetii infections (including pregnant women)<br>Other Coxiella burnetii infections (including pregnant women) | Biological: Blood sampling<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of a complication, linked to the rate of autoantibodies. | The required complications are the followings: endocarditis thrombosis thrombocytopenia obstetrical complications: Spontaneous miscarriage defined as a spontaneous expulsion of the embryo before 20 weeks gestation . Spontaneous abortion Fetal intrauterine death Oligoamnios Intrauterine growth retardation Fetal malformations . | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of anti- cardiolipin antibodies |  | 1 day | 
| Rate of anti- phagosome autoantibodies |  | 1 day |